Anal Cancer News and Research

RSS

Anal cancer is a type of cancer which arises from the anus, the distal orifice of the gastrointestinal tract. It is a distinct entity from the more common colorectal cancer.

IRCI to design and fund clinical trials for rare cancers

Cancer Research UK will join forces with international research groups from the UK, Europe and the US to launch an initiative to boost the development of new treatments for patients with rare cancers. The announcement will be made by Dr Harpal Kumar, chief executive of Cancer Research UK, at the 2011 World Cancer Leaders' Summit taking place today in Dublin.

18 Nov 2011

Solid organ transplant may increase risk of cancer

Patients who have received a solid organ transplant, such as kidney, liver, heart or lung, have an overall cancer risk that is double that of the general population, with an increased risk for many different types of malignancies, according to a study in the November 2 issue of JAMA.

2 Nov 2011

Gardasil vaccine safe and effective against anal cancer

A large, international clinical trial led by doctors at the University of California, San Francisco indicates that a vaccine to prevent anal cancer is safe and effective, according to a study reported in the Oct. 27, 2011 issue of New England Journal of Medicine.

27 Oct 2011

Routine HPV vaccine for boys advised by health advisory panel

A government advisory panel on Tuesday decided that the vaccine against cervical cancer causing virus – HPV (Human Papilloma Virus) should also be given to boys, in part to help prevent the cancer-causing virus through sex. The HPV virus has been recommended for girls aged 9 to 26 since 2006.

26 Oct 2011

RAZCER (Rapid Astrazeneca and CARO Evaluation of Radio-modifiers) awards announced - five Canadians win

Five leading Canadian radiation oncologists receive RAZCER Awards of $22,727 each for novel studies of radiation-drug interactions that have the potential to either protect normal tissues or sensitize tumours, and thus to enhance the effectiveness of radiation therapy for cancer patients. A selection committee of members of the Canadian Association of Radiation Oncology (CARO) selected the 2011 recipients from among a field of 12 applicants. Astrazeneca provides the funds for the RAZCER Award as an educational grant.

13 Oct 2011

HPV may be responsible for the alarming numbers of oral cancers: Study

Sore throat for a very long time could be an early precursor of a sexually transmitted virus that is fueling a rise in oral cancer suggest researchers. Between 1988 and 2004, head, neck and throat cancers that tested positive for the human papilloma virus rose an astounding 225 percent, according to a new study.

4 Oct 2011

Merck issues statement on GARDASIL human papillomavirus vaccine

Merck, known as MSD outside the United States and Canada, issued the following statement on GARDASIL, Merck's vaccine to protect against certain diseases caused by human papillomavirus (HPV) types 6, 11, 16 and 18.

14 Sep 2011

ASTRO to honor two radiation oncologists with 2011 Gold Medal award

The American Society for Radiation Oncology has selected K. Kian Ang, MD, PhD, FASTRO, and Bernard Cummings, MB, ChB, FASTRO, as the Society's 2011 Gold Medal recipients.

26 May 2011

Rwanda, QIAGEN and Merck launch comprehensive national cervical cancer prevention program

The Government of Rwanda, together with QIAGEN N.V. and Merck, known as MSD outside the United States and Canada, today announced the launch, in Kigali, Rwanda, of a comprehensive national cervical cancer prevention program that includes vaccination with GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for appropriate girls 12 to 15 years of age and modern molecular diagnostic screening for women between the ages of 35 and 45.

From QIAGEN Manchester Limited 25 Apr 2011

Oral sex linked to cancer

Researchers from the United States have said that there is strong evidence linking oral sex to cancer. They have urged more study of how human papillomaviruses may be to blame for a rise in oral cancer among white men.

20 Feb 2011

Anti-cancer shots for boys in the pipeline

The Pharmaceutical Benefits Advisory Committee (PBAC) is deciding on whether to include the human papillomavirus (HPV) vaccine, Gardasil in in the National Immunization Program for boys.

8 Feb 2011

HPV vaccine can prevent 90% of genital warts in men: Study

The vaccine for human papillomavirus can prevent 90 percent of genital warts in men when offered before exposure to the four HPV strains covered by the vaccine, according to a new multi-center study led by H. Lee Moffitt Cancer Center and UCSF.

4 Feb 2011

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

Merck announced today that data from the pivotal Phase III study with GARDASIL in males were published in the February 3 issue of the New England Journal of Medicine.

3 Feb 2011

Men are more willing to receive HPV vaccine, trend may help reduce cancer deaths

Men are more willing to receive human papillomavirus vaccine when they learn the vaccine can prevent cancer, according to a recent University of North Carolina at Chapel Hill study.

5 Jan 2011

Merck announces FDA approval for GARDASIL against HPV-related anal cancer

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] for the prevention of anal cancer caused by human papillomavirus (HPV) types 16 and 18 and for the prevention of anal intraepithelial neoplasia (AIN) grades 1, 2 and 3 (anal dysplasias and precancerous lesions) caused by HPV types 6, 11, 16 and 18, in males and females 9 through 26 years of age.

23 Dec 2010

FDA approves Gardasil for prevention of anal cancer

The U.S. Food and Drug Administration today approved the vaccine Gardasil for the prevention of anal cancer and associated precancerous lesions due to human papillomavirus (HPV) types 6, 11, 16, and 18 in people ages 9 through 26 years.

23 Dec 2010

NIAID scientists confirm antiviral activity of two lead compounds against HPV

Tamir Biotechnology, Inc. announced today that scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID) reported test results confirming two of our lead compounds showed excellent in vitro antiviral activity and no cellular toxicity at dose levels tested for Human Papillomavirus (HPV).

30 Nov 2010

Merck announces FDA Advisory Committee approval of GARDASIL for anal cancer and AIN treatment

Merck announced today that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee has advised that the data presented support an indication for GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] for the prevention of anal cancer and anal intraepithelial neoplasia (AIN) in both males and females 9 through 26 years of age.

18 Nov 2010

Results from AMRI's on-going Phase I clinical study of ALB 109564(a) published online

AMRI announced today that on-going results from its Phase I clinical study on its novel tubulin inhibitor, ALB 109564(a), were published on the website of the American Society of Clinical Oncology (abstract.asco.org/alb). These results indicate that ALB 109564(a) is well tolerated at the doses tested and shows preliminary evidence of clinical activity in disease types not typically treated with approved vinca alkaloids.

2 Jun 2010

In addition to anal and cervical cancer, HPV can also cause head and neck cancer

The Human Papillomavirus (HPV) is the causative agent responsible for most cases of cervical cancer, but is also associated with several other types of cancer.

12 Mar 2010